Abstract
Today, consumers are taking a more proactive approach to managing their health and the prevention of diet-related diseases, such as obesity, diabetes, cardiovascular and bone and joint diseases. Many of these diseases are at epidemic levels, and this combined with increasing patient power makes the prevention of these lifestyle diseases attractive markets for both the food and pharmaceutical industries to exploit. Next-Generation Nutraceuticals is a new report published by Business Insights that provides analysis of how the food and pharmaceutical industries are becoming more aligned in their approach to consumer health. This report assesses the changing regulatory landscape in addition to how the strategies of leading ingredients, food, drinks and pharmaceutical companies are evolving in the new consumer health marketplace. Understand how food and drinks manufacturers are applying genomic and proteomic technologies that are widely used in the pharmaceutical industry in order to create increasingly sophisticated functional food products with this new report.
Table of Contents
Executive Summary
- Food and pharmaceutical disease prevention
- Functional food and drinks
- Technologies for nutrigenomics
- The regulatory landscape
- Strategies of leading ingredient, food, drinks and pharma companies
- Future challenges and opportunities
Chapter 1 Food and pharmaceutical disease
- prevention
- Summary
- Introduction
- The changing approach to the health burden
- New technologies
- Key convergent markets
- Obesity
- Epidemiology
- Sales
- Cardiovascular disease
- Epidemiology
- Sales
- Diabetes
- Epidemiology
- Sales
- Bone health
- Epidemiology
- Sales
- Conclusions
Chapter 2 Functional food and drinks
- Summary
- Introduction
- Functional food and drinks
- Functional ingredients
- Scientific evidence to support the health benefits of functional
ingredients
- Proving efficacy: pharma vs. food
- Growth areas and product trends in the functional foods market
- Heart health
- Digestive health - Probiotics
- Innovative ingredients aligning with pharma
- Personalized nutrition
- Conclusions
Chapter 3 Technologies for nutrigenomics
- Summary
- Introduction
- Biomic technologies in the pharma industry
- Pharma technologies in the food industry
- Genomics
- Genomics in personalized nutrition
- Case study: Sciona Inc
- Transcriptomics
- Transcriptomics in the food industry
- Case study: WellGen Inc.
- Proteomics
- Metabolomics
- Case study: the INTERMAP study
- Challenges to metabolomics in nutrition research
- Growth and interest in metabolomics
- Systems Biology
- Nanotechnology delivering new ingredients
- Conclusions
Chapter 4 The regulatory landscape
- Summary
- Introduction
- Regulation of health claims for functional foods
- Japan
- United States
- Health claims
- Structure/function claims
- Criticism of the FDA' s approach
- Europe
- Opportunities and threats of functional food regulation
- The future of functional food regulation
- Regulation of personalized dietary advice
- Conclusions
Chapter 5 Strategies of leading ingredient,
- food, drinks and pharma
- companies
- Summary
- Introduction
- Ingredient manufacturers
- DSM
- BASF
- Chr. Hansen
- Products
- Research
- Opportunities for the ingredients industry
- Food and drinks manufacturers
- Nestlé
- Nestlé' s products
- Research
- The future for Nestlé
- Unilever
- Unilever' s products
- Research
- The future for Unilever
- Ajinomoto
- Research and the future for Ajinomoto
- Danone
- The future for Danone
- Coca-Cola
- Other food and drinks manufacturers
- Pharma companies
- Future trends for the food and pharma industries
- Agribusiness
- Alliances
- Food-pharma alliances
- Alliances with new technology companies
- Alliances for nutrigenomic research
- Conclusions
Chapter 6 Future challenges and
- opportunities
- Summary
- Introduction
- Opportunities and market drivers
- Consumer demand
- Incentives
- Opportunities in developing markets
- New product development opportunities
- Marketing
- Challenges
- Scientific challenges
- Furthering basic and applied research
- Clinical testing of nutraceuticals
- Defining health
- Ethical, legal and societal concerns
- Ethical concerns
- Societal concerns
- Privacy and human rights
- Research practices in nutrigenomics
- The regulatory framework
- Conclusions
Chapter 7 Appendix
- Bibliography
- Index
- Footnotes
List of Figures
- Figure 1.1: Drivers of change in the food and pharma industries
- Figure 1.2: Examples of food and pharma approaches to heart disease
- Figure 1.3: A functional food pyramid
- Figure 1.4: The role of food and pharmaceuticals in the healthcare continuum
- Figure 1.5: Examples of obesity drugs in development
- Figure 1.6: Global deaths from cardiovascular disease
- Figure 1.7: Drugs in clinical development for CV disorders
- Figure 2.8: Top US consumer health concerns, 2005
- Figure 2.9: Nutrigen IQ3 Yogurt Drink
- Figure 2.10: Right Direction Cookies
- Figure 2.11: DanaCol with Omega-3 & Plant Sterols Dairy Drink
- Figure 2.12: Calpis Aqua Nyusankin
- Figure 2.13: Calpis Interbalance L-92 Lactic Acid Bacteria Drink
- Figure 3.14: The ' omics technologies: definitions
- Figure 3.15: The ' omics technologies
- Figure 3.16: The Cellf™ Assessment Kit from Sciona
- Figure 3.17: Pro-inflammatory metabolic pathways
- Figure 3.18: Technologies used in proteomics
- Figure 3.19: 1H NMR spectrum of urine showing functional windows
- Figure 3.20: Large scale metabolomic screening of human populations: identifying outliers
- Figure 4.21: Standardized qualifying language for qualified health claims
- Figure 4.22: Examples of structure/function claims allowed on food labeling
- Figure 5.23: Recent products launched that contain TEAVIGO™
- Figure 5.24: Development of new probiotic cultures at Chr. Hansen
- Figure 5.25: Nestlé' s products by functional category, 2004-2006
- Figure 5.26: Nestlé' s functional brands (2005)
- Figure 5.27: Nestle NesVita Pro-Heart Probiotic Drink
- Figure 5.28: Unilever' s products by functional category, 2004-2006
- Figure 5.29: Flora Pro-Active Blood Pressure Mini Drink
- Figure 5.30: Ajinomoto products by functional category, 2004-2006
- Figure 5.31: Calpis Ameal S Maiasa Yasai (vegetable breakfast drink)
- Figure 5.32: Danone' s products by functional category, 2004-2006
- Figure 5.33: Danone Petit Danone Cheese Dessert
- Figure 5.34: Coca-Cola' s products by functional category, 2004-2006
- Figure 5.35: Enviga
- Figure 5.36: Novartis' Benefiber Clear Choice! Powder and Isocal Jelly Arg Jelly Dessert
- Figure 6.37: Awareness and favorability towards personalized nutrition
List of Tables
- Table 1.1: Number and percentage of overweight and obese adults by country, 2005-2010 (% adult population)
- Table 1.2: Size of the diet food and drinks market and the obesity pharmaceutical market, (US$,m), 2005-2010
- Table 1.3: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2004
- Table 1.4: Size of the food and drinks and pharmaceutical markets for heart health, (US$,m), 2005-2010
- Table 1.5: Prevalence of type-2 diabetes in the 7 major markets, 2005-11
- Table 1.6: Size of the pharmaceutical market for diabetes, (US$,m), 2005-2010
- Table 1.7: Prevalence of Rheumatoid Arthritis based on population > 60 in the seven major markets (000s), 2005-2010
- Table 1.8: Prevalence of osteoporosis in men and women over 50 across the seven major markets, 2005
- Table 1.9: Size of the food and drinks and pharmaceutical markets for bone health, (US$m), 2005-2010
- Table 2.10: Functional ingredients
- Table 2.11: Functional food ingredients (cont.)
- Table 2.12: Examples of functional food ingredients and the scientific basis for health benefit claims
- Table 2.13: Functional food and drink sales by value ($m), 2005-2008
- Table 3.14: Companies offering nutrigenetic testing and dietary advice, 2006
- Table 3.15: Genetic variations screened by the Cellf™ Assessment Kit from Sciona, 2006
- Table 3.16: How nutrients alter gene expression
- Table 3.17: Examples of transcriptomics in nutritional biology and nutrigenomics
- Table 3.18: Companies and research centres utilizing gene expression analysis for nutrigenomic applications
- Table 4.19: FOSHU functions and functional food components
- Table 4.20: Generic health claims currently approved by the FDA
- Table 4.21: Regulatory opportunities and threats in the functional foods industry
- Table 5.22: Ajinomoto products containing AmealPeptide™ launched in Japan
- Table 5.23: Recent functional food and drinks launches
- Table 5.24: Some functional food and drink products launched by pharma companies
- Table 5.25: Consortia involved in the International Nutrigenomics Network
- Table 5.26: Examples of other collaborative nutrigenomic research projects
- Table 6.27: Biomarkers for well-being and disease risk reduction
